MARINUS PHARMACEUTICALS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Revenue:
Product revenue, net
Collaboration revenue
Total revenue
Federal contract revenue
Total revenue
Expenses:
Research and development
General and administrative
Selling, general and administrative
Cost of revenue
Product revenue, net
Collaboration revenue
Total cost of revenue
Cost of IP license fee
Total expenses
Loss from operations
Interest income
Interest expense
(Loss) gain from sale of priority review voucher, net
Other income (expense), net
Loss before income taxes
Benefit (provision) for income taxes
Net loss and comprehensive loss
Deemed Dividends
Net loss applicable to common shareholders
Net loss per share of common stock-basic and diluted
Basic and diluted weighted average shares outstanding
Per share information:
Net loss per share of common stock-basic
Net loss per share of common stock-diluted
Basic weighted average shares outstanding
Diluted weighted average shares outstanding
Other comprehensive loss:
Unrealized loss on available-for-sale securities
Total comprehensive loss

Comments